Loading...

BioArctic

DB:B9A
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
B9A
DB
SEK7B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

BioArctic AB (publ), a research intensive biopharmaceutical company, develops disease modifying treatments and diagnostics for neurodegenerative diseases in Sweden. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
  • BioArctic has significant price volatility in the past 3 months.
B9A Share Price and Events
7 Day Returns
-5%
DB:B9A
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-
DB:B9A
-5.6%
DE Biotechs
-4.5%
DE Market
B9A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioArctic (B9A) -5% 1.5% -8.8% - - -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • No trading data on B9A.
  • No trading data on B9A.
Price Volatility
Industry
5yr Volatility vs Market

B9A Value

 Is BioArctic undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BioArctic. This is due to cash flow or dividend data being unavailable. The share price is €7.37.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioArctic's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioArctic's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:B9A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK4.33
OM:BIOA B Share Price ** OM (2019-04-25) in SEK SEK80.5
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioArctic.

DB:B9A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:BIOA B Share Price ÷ EPS (both in SEK)

= 80.5 ÷ 4.33

18.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioArctic is good value based on earnings compared to the Europe Biotechs industry average.
  • BioArctic is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does BioArctic's expected growth come at a high price?
Raw Data
DB:B9A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 18.58x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-85%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

DB:B9A PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 18.58x ÷ -85%

-0.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioArctic earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioArctic's assets?
Raw Data
DB:B9A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK11.56
OM:BIOA B Share Price * OM (2019-04-25) in SEK SEK80.5
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:B9A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:BIOA B Share Price ÷ Book Value per Share (both in SEK)

= 80.5 ÷ 11.56

6.97x

* Primary Listing of BioArctic.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioArctic is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess BioArctic's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioArctic has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

B9A Future Performance

 How is BioArctic expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-85%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioArctic expected to grow at an attractive rate?
  • BioArctic's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • BioArctic's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • BioArctic's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:B9A Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:B9A Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -85%
DB:B9A Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts -74.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:B9A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:B9A Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 85 -153 -153 2
2020-12-31 48 -228 -192 2
2019-12-31 320 344 65 2
DB:B9A Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 722 -200 382
2018-09-30 250 -157 58
2018-06-30 187 -149 32
2018-03-31 167 -139 29
2017-12-31 157 -135 15
2017-09-30 184 616 78
2017-06-30 154 630 71
2017-03-31 127 647 64
2016-12-31 106 675 58

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioArctic's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • BioArctic's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:B9A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from BioArctic Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:B9A Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -1.73 -1.43 -2.04 2.00
2020-12-31 -2.19 -1.84 -2.54 2.00
2019-12-31 0.74 0.92 0.55 2.00
DB:B9A Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 4.33
2018-09-30 0.67
2018-06-30 0.42
2018-03-31 0.39
2017-12-31 0.22
2017-09-30 1.24
2017-06-30 1.07
2017-03-31 1.04
2016-12-31 0.91

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioArctic will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess BioArctic's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioArctic has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

B9A Past Performance

  How has BioArctic performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioArctic's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient data to establish if BioArctic's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare BioArctic's 1-year earnings growth to the 5-year average due to insufficient past data.
  • BioArctic's earnings growth has exceeded the Europe Biotechs industry average in the past year (2417.7% vs 18.2%).
Earnings and Revenue History
BioArctic's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioArctic Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:B9A Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 722.22 381.60 88.99
2018-09-30 249.67 58.23 41.72 101.58
2018-06-30 187.12 32.26 40.37 101.58
2018-03-31 166.84 29.46 36.21 121.48
2017-12-31 156.83 15.16 69.13
2017-09-30 184.12 78.29 53.72 22.08
2017-06-30 153.81 70.64 41.02 30.95
2017-03-31 126.79 63.51 17.49 59.66
2016-12-31 105.61 57.58 15.91 53.67
2015-12-31 41.57 3.71 6.01 38.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • BioArctic has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • BioArctic used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • BioArctic has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess BioArctic's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioArctic has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

B9A Health

 How is BioArctic's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioArctic's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioArctic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioArctic's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioArctic's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BioArctic has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioArctic Company Filings, last reported 3 months ago.

DB:B9A Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,017.74 0.00 917.31
2018-09-30 682.53 0.00 1,008.52
2018-06-30 656.67 0.00 1,041.74
2018-03-31 651.55 0.00 1,078.75
2017-12-31 636.13 0.00 1,110.37
2017-09-30 64.08 0.00 590.68
2017-06-30 64.20 0.00 622.06
2017-03-31 60.76 0.00 692.53
2016-12-31 60.76 0.00 692.53
2015-12-31 108.29 0.00 113.83
  • BioArctic has no debt.
  • BioArctic has not taken on any debt in the past 5 years.
  • BioArctic has no debt, it does not need to be covered by operating cash flow.
  • BioArctic has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess BioArctic's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioArctic has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

B9A Dividends

 What is BioArctic's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.86%
Current annual income from BioArctic dividends. Estimated to be 0% next year.
If you bought €2,000 of BioArctic shares you are expected to receive €37 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • BioArctic's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.44%).
  • BioArctic's dividend is below the markets top 25% of dividend payers in Germany (3.67%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:B9A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:B9A Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00
DB:B9A Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2019-04-10 1.500 1.869
2017-11-08 0.000 0.000
2017-10-12 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • It is too early to tell whether BioArctic has stable dividend payments.
  • BioArctic only just started paying a dividend, it is too early to tell if payments are increasing.
Current Payout to shareholders
What portion of BioArctic's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.9x coverage).
Future Payout to shareholders
  • No need to calculate the sustainability of BioArctic's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess BioArctic's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioArctic afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioArctic has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

B9A Management

 What is the CEO of BioArctic's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gunilla Osswald
COMPENSATION SEK3,481,000
AGE 57
TENURE AS CEO 5.3 years
CEO Bio

Ms. Gunilla Osswald has been the Chief Executive Officer at BioArctic AB (publ) since 2014. Ms. Osswald has been a Director of PledPharma AB since 2017. She is a Pharmacist and Doctor in Biopharmacy and Pharmacokinetics at Uppsala University. She served as President at BioArctic AB (publ) until 2019.

CEO Compensation
  • Gunilla's compensation has been consistent with company performance over the past year.
  • Gunilla's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BioArctic management team in years:

8.8
Average Tenure
59
Average Age
  • The average tenure for the BioArctic management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Gunilla Osswald

TITLE
Chief Executive Officer
COMPENSATION
SEK3M
AGE
57
TENURE
5.3 yrs

Pär Gellerfors

TITLE
Co-Founder
COMPENSATION
SEK2M
AGE
71
TENURE
16.3 yrs

Lars Lannfelt

TITLE
Co-Founder
COMPENSATION
SEK1M
AGE
69
TENURE
16.3 yrs

Jan Mattsson

TITLE
VP of Finance & CFO
AGE
58
TENURE
2.3 yrs

Christer Möller

TITLE
VP of Pre-Clinical Development & Chief Scientific Officer
AGE
59
TENURE
13.3 yrs

Christina Astren Eriksson

TITLE
IR & Communications Director
AGE
59
TENURE
2.3 yrs

Gunilla Andersson

TITLE
Senior Director HR
AGE
57
TENURE
0.3 yrs

Hans Basun

TITLE
VP of Clinical Development & Chief Medical Officer
AGE
69
TENURE
12.3 yrs
Board of Directors Tenure

Average tenure and age of the BioArctic board of directors in years:

2.3
Average Tenure
69.5
Average Age
  • The average tenure for the BioArctic board of directors is less than 3 years, this suggests a new board.
Board of Directors

Wenche Rolfsen

TITLE
Chairman
COMPENSATION
SEK279K
AGE
66
TENURE
1.6 yrs

Ivar Verner

TITLE
Deputy Chairman
COMPENSATION
SEK173K
AGE
71
TENURE
2.3 yrs

Pär Gellerfors

TITLE
Co-Founder
COMPENSATION
SEK2M
AGE
71
TENURE
16.3 yrs

Lars Lannfelt

TITLE
Co-Founder
COMPENSATION
SEK1M
AGE
69
TENURE
16.3 yrs

Konrad Beyreuther

TITLE
Member of the Scientific Board

Martin Ingelsson

TITLE
Member of Scientific Board

Hans Ekelund

TITLE
Director
COMPENSATION
SEK175K
AGE
70
TENURE
5.3 yrs

Eugen Steiner

TITLE
Director
COMPENSATION
SEK150K
AGE
64
TENURE
1.6 yrs

Mikael Smedeby

TITLE
Director
COMPENSATION
SEK131K
AGE
50
TENURE
0.9 yrs

Hans Wigzell

TITLE
Member of Scientific Advisory Board
AGE
80
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by BioArctic insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
22. Feb 19 Buy Wenche Rolfsen Individual 21. Feb 19 22. Feb 19 705 €9.63 €6,743
X
Management checks
We assess BioArctic's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioArctic has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

B9A News

Simply Wall St News

B9A Company Info

Description

BioArctic AB (publ), a research intensive biopharmaceutical company, develops disease modifying treatments and diagnostics for neurodegenerative diseases in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 2b clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer’s disease; and is in preclinical trials for treating Down’s syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer’s disease. The company also develops AE1501, AD1502, and AD1503 disease modifying treatments for prodromal and mild Alzheimer’s disease; BAN0805, an anti-alpha-synuclein for treating Parkinson’s disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for complete spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer’s disease; imaging and biochemical biomarkers for Parkinson’s disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai Co., Ltd. and AbbVie Inc.; and a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostic methods for Alzheimer's disease. BioArctic AB (publ) was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is headquartered in Stockholm, Sweden.

Details
Name: BioArctic AB (publ)
B9A
Exchange: DB
Founded: 1992
SEK667,744,942
88,059,985
Website: http://www.bioarctic.se
Address: BioArctic AB (publ)
Warfvinges vag 35,
Stockholm,
Stockholm County, 112 51,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM BIOA B Class B Shares OMX Nordic Exchange Stockholm SE SEK 12. Oct 2017
DB B9A Class B Shares Deutsche Boerse AG DE EUR 12. Oct 2017
LSE 0RV2 Class B Shares London Stock Exchange GB SEK 12. Oct 2017
BATS-CHIXE BIOABS Class B Shares BATS 'Chi-X Europe' GB SEK 12. Oct 2017
Number of employees
Current staff
Staff numbers
31
BioArctic employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 23:27
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/03/28
Last earnings filing: 2019/04/16
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.